Company
Junshi Biosciences
Junshi Biosciences has 5 drugs tracked on RxWires: 1 in Phase 2, 4 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Short-course Radiotherapy, SCRT | Phase 2 | Rectal Adenocarcinoma |
| TAB006 | Phase 1 | Previously Treated, Advanced |
| Part A | Phase 1 | Advanced Malignancies |
| TAB004 | Phase 1 | Advanced Unresectable Solid Tumor |
| JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody | Phase 1 | Neoplasm Malignant |
Latest
No recent events.
Follow Junshi Biosciences on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.